Table 3 |
||
|
Incidence of grade 3/4 adverse events in a randomized study of rituximab plus CHOP versus CHOP alone in elderly patients with diffuse, large B cell lymphoma |
||
|
Regimen |
||
|
|
||
|
Adverse event |
CHOP |
Rituximab + CHOP |
|
|
||
|
Any grade 3/4 adverse event (including grade 2 infections) |
145 (74.0) |
159 (78.7) |
|
Infections |
||
|
Bronchitis |
16 (8.2) |
22 (10.9) |
|
Urinary tract infection |
17 (8.7) |
19 (9.4) |
|
Pneumonia |
13 (6.6) |
10 (5.0) |
|
Febrile neutropenia |
47 (24.0) |
45 (22.3) |
|
Respiratory disorders |
||
|
Dyspnoea |
6 (3.1) |
16 (7.9) |
|
Cough |
6 (3.1) |
8 (4.0) |
|
Rhinitis |
5 (2.6) |
1 (0.5) |
|
General disorders and administration site disorders |
||
|
Pyrexia |
32 (16.3) |
26 (12.9) |
|
Fatigue |
13 (6.6) |
8 (4.0) |
|
General physical health deterioration |
10 (5.1) |
10 (5.0) |
|
Gastrointestinal disorders |
||
|
Vomiting |
12 (6.1) |
8 (4.0) |
|
Abdominal pain |
7 (3.6) |
12 (5.9) |
|
|
||
|
Values are expressed as n (%). CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone. Data from [30]. |
||
|
Hainsworth Arthritis Res Ther 2003 5(Suppl 4):S12 doi:10.1186/ar1008 |
||